Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Characterizing the Interactome of the MET Exon 14 Oncogene in Lung Adenocarcinoma

EF 2023-24

Résumé
Lung cancer is the leading cause of cancer death worldwide. Despite decades of advancements, long-term survival for patients with advanced lung cancer remains low. Thus, it is imperative to establish more robust and personalized treatment plans for treating this disease. Mutations in the hepatocyte growth factor receptor (MET) are commonly observed in lung cancers and contribute to disease development and resistance to cancer therapeutics. Little research has been done to understand how these cancer-causing MET mutants change the way they interact with other proteins in the cell, and how this can alter cell function and contribute to cancer development. Elucidating these interactions would allow for better understanding of how these MET mutants behave, so that we can better map out the molecular pathways they rely on to promote disease development and progression. I hypothesize that the mutant MET receptor changes the way it interacts with other proteins around it, and that these changes contribute to MET’s role in cancer development. To investigate this, I will start by comparing and contrasting the protein interactions of mutated and unmutated forms of MET. This will allow me to determine which proteins preferentially interact with the mutant MET receptor to promote cancer development. Once I validate these interactions, I will examine how interfering with the function of these interactors affects cell function, and more importantly, whether this could affect disease development. By identifying and better understanding these interactions, I will therefore better understand the mechanisms contributing to lung cancer development and identify molecular players which could be targeted therapeutically to improve patient outcomes.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
506440
Name
Okun Sarah Anna
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterizing the Interactome of the MET Exon 14 Oncogene in Lung Adenocarcinoma
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Crispr; Genetic Mutation; Interactome; Lung Adenocarcinoma; Oncogene; Protein Interactions; Signaling Pathways; Targeted Therapy; Tmt Mass Spectrometry
Abstract
Lung cancer is the leading cause of cancer death worldwide. Despite decades of advancements, long-term survival for patients with advanced lung cancer remains low. Thus, it is imperative to establish more robust and personalized treatment plans for treating this disease. Mutations in the hepatocyte growth factor receptor (MET) are commonly observed in lung cancers and contribute to disease development and resistance to cancer therapeutics. Little research has been done to understand how these cancer-causing MET mutants change the way they interact with other proteins in the cell, and how this can alter cell function and contribute to cancer development. Elucidating these interactions would allow for better understanding of how these MET mutants behave, so that we can better map out the molecular pathways they rely on to promote disease development and progression. I hypothesize that the mutant MET receptor changes the way it interacts with other proteins around it, and that these changes contribute to MET’s role in cancer development. To investigate this, I will start by comparing and contrasting the protein interactions of mutated and unmutated forms of MET. This will allow me to determine which proteins preferentially interact with the mutant MET receptor to promote cancer development. Once I validate these interactions, I will examine how interfering with the function of these interactors affects cell function, and more importantly, whether this could affect disease development. By identifying and better understanding these interactions, I will therefore better understand the mechanisms contributing to lung cancer development and identify molecular players which could be targeted therapeutically to improve patient outcomes.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Okun, Sarah Anna
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~